|
PRINCIPAL RESEARCHER |
PROJECT |
FUNDING AGENCY |
|
Martínez Valderde A. |
Estudio de los mecanismos de resistencia a la insulina: implicaciones en obesidad, diabetes y síndrome metabólico (S2010/BMD-2423). |
CAM. 2012-2016. |
|
Cuadrado Pastor A. |
Papel de NRF2 como modulador antioxidante de la neuroinflamación en la enfermedad de Alzheimer (SAF2013-43271-R). |
MINECO. 2014-2016 |
|
Cuadrado Pastor A. |
Red de investigación en NRF2 como nodo del "patogenosoma" (SAF2015-71304-REDT). |
MINECO. 2015-2017. |
|
Martínez Valderde A. |
Inflammation associated with cronic metabolic damage in diabetes mellitus and its complications (SAF2015-65267-R). |
MINECO. 2016-2018. |
|
Cuadrado Pastor A.
|
Targeting NRF2 with SFX-01 to modify parkinson’s disease progression in the AAV6-α-synuclein
mouse model.
|
Evgen. 2016 |
|
Martínez Valverde A. |
Desarrollo de mecanismo de acción del glicinato de metformina en un modelo de hepatocitos. |
Laboratorios Silanes. 2015. |
|
Antonio Cuadrado Pastor |
Targeting Nrf2 with BG-12 to modify Parkinson’s disease progression in the AAV6-α-synuclein mouse model |
Biogen |
|
Antonio Cuadrado Pastor |
WNT signaling: biomarker and target evaluation in Alzheimer’s disease |
Network of Centres of Excellence in Neurodegeneration (COEN) |
|
Ángela Martínez Valverde |
Effect of GLP-1 on the gut-to-liver axis in the hepatoprotection against non-alcoholic fatty liver disease |
European Foundation for the study
of Diabetes
|
|
Ángela Martínez Valverde |
Neurodegeneration as an early event in the Pathogenesis of Diabetic Retinopathy: a multicentric, prospective, phase II-III, double blind randomized controlled trial to assess the efficacy of neuroprotective administered topically to prevent or arrest Diabetic Retinopathy (EUROCONDOR) |
European Union |
|
Ángela Martínez Valverde |
Estudio de los mecanismos de resistencia a la insulina: implicaciones en obesidad, diabetes y síndrome metabólico |
Comunidad de Madrid |
|
Ángela Martínez Valverde |
Colaboración para el fomento de la investigación desarrollada en el grupo IdiPAZ: “Estrategias neuroprotectoras en enfermedades neurodegenerativas” |
Consejo Superior de Investigación Científica |
|
Ángela Martínez Valverde |
Inhibition of protein tyrosine phosphatase 1B in the treatment of type 2 diabetes: effects in diabetic complications and cell proliferation |
Ministerio de Economía y Competitividad |
|
2013 |
Colaboración para el fomento de la Investigación desarrollada en el Grupo IdiPAZ “Estrategias neuroprotectoras en Enfermedades Neurodegenerativas |
Consejo Superior de Investigación
Científica |
|
2013 |
WNT signaling: biomarker and target evaluation in Alzheimer’s disease |
Network of Centres of Excellence in
Neurodegeneration (COEN) |
|
2013 |
Papel de factor de transcripción Nrf2 en diferenciación neuronal, neuroprotección, neuroinflamación |
Ministerio de Economía y Competitividad |
|
2013 |
Factor de transcripción Nrf2 como nueva diana terapéutica para la enfermedad de Parkinson |
Instituto de Salud Carlos III |
|
2013 |
Targeting Nrf2 with BG-12 to modify Parkinson’s disease progression in the AAV6-α-synuclein mouse model |
Biogen Idec |
|
2013 |
Study of new targets for treatment of acute liver failure by in vivo siRNA administration in mice |
Fundación Hoffmann-La Roche |
|
2013 |
Effect of GLP-1 on the gut-to-liver axis in the hepatoprotection
against non-alcoholic fatty liver disease |
European Foundation for the Study of Diabetes |
|
2013 |
Neurodegeneration as an early event in the Pathogenesis of Diabetic Retinopathy: a multicentric, prospective, phase II-III, double blind randomized controlled trial to assess the efficacy of neuroprotective administered topically to prevent or arrest Diabetic Retinopathy (EUROCONDOR) |
European Union |
|
2013 |
Estudio de los mecanismos de resistencia a la insulina: implicaciones en obesidad, diabetes y síndrome metabólico |
Comunidad de Madrid |
|
2013 |
Role of oxintomodulin in hepatic regeneration in a model of NASH |
Medimmune (AstraZeneca) |
|
2013 |
Validation of anti-gremlin antibody for kidney fibrosis: in vitro and in vivo approaches |
Medimmune (AstraZeneca) |
|
2013 |
Inhibition of protein tyrosine phosphatase 1B in the treatment of type 2 diabetes: effects in diabetic complications
and cell proliferation |
Ministerio de Economía y Competitividad |
|
2012 |
Papel del factor de transcripción Nrf2 en diferenciación neuronal, neuroprotección y neuroinfl amación |
Ministerio de Economía y Competitividad |
|
2012 |
El factor de transcripción Nrf2 como nueva diana terapéutica
para la enfermedad de Parkinson |
Instituto de Salud Carlos III |
|
2012 |
Sulforaphane as a nutritional supplement to activate the transcription factor Nrf2 in the brain and modify Alzheimer’s disease progression |
Nutricia Research Foundation |
|
2011 |
The transcription factor Nrf2 as a target to reduce neurodegeneration and neuroinflammation in Parkinson’s disease |
MICHAEL J FOX FUNDATION FOR PARKINSON’S RESEARCH |